27.36 USD
↘ 0.17 (0.62%)AT CLOSE (11:59 AM EDT)
Rigel Pharmaceuticals Inc. (New)
RIGLNASDAQ • USD
27.37
↗ 0.01 (0.02%)
POST MARKET (AS OF 05:41 PM EDT)
Post Market
AS OF 05:41 PM EDT
27.37
↗ 0.01 (0.02%)
Market: OPEN
Open?$27.58
High?$27.95
Low?$27.13
Prev. Close?$27.53
Volume?202.9K
Avg. Volume?374.6K
VWAP?$27.54
Rel. Volume?0.54x
Bid / Ask
Bid?$23.87 × 100
Ask?$31.37 × 100
Spread?$7.50
Midpoint?$27.62
Valuation & Ratios
Market Cap?508.6M
Shares Out?18.5M
Float?17.5M
Float %?97.3%
P/E Ratio?1.39
P/B Ratio?1.30
EPS?$19.87
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.42Strong
Quick Ratio?2.30Strong
Cash Ratio?0.41Low
Debt/Equity?0.13Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?1.4CHEAP▾
P/B?1.30CHEAP▾
P/S?1.73CHEAP▾
P/FCF?6.7CHEAP▾
EV/EBITDA?4.1CHEAP▾
EV/Sales?1.77CHEAP▾
Returns & Efficiency
ROE?93.8%STRONG▾
ROA?71.5%STRONG▾
Cash Flow & Enterprise
FCF?$75.6M
Enterprise Value?$520.3M
Related Companies
Loading...
News
Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Address
611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100